SCHEMBL2118767

SCHEMBL2118767

C=CCOC(=O)CCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
NR5A2 O00482 1/20 0.47
NR5A1 Q13285 1/20 0.47
MAPT P10636 2/20 0.46
ADRA1A P35348 2/20 0.46
LMNA P02545 1/20 0.46
ESR1 P03372 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CDC25A P30304 1/20 0.46
AGTR1 P30556 1/20 0.46
AKT1 P31749 1/20 0.46
KCNH2 Q12809 1/20 0.46
ADRA2A P08913 1/20 0.45
BLM P54132 1/20 0.44
TSHR P16473 1/20 0.41
PLA2G1B P04054 1/20 0.40
PLA2G2A P14555 1/20 0.40
RECQL P46063 1/20 0.39
ADRA1D P25100 1/20 0.39
PTAFR P25105 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118106 0.86 SMN1; SMN2 (0.48) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL170993 0.82 LMNA (0.56) SMN1; SMN2MAPTADRA1ALMNAESR1
SCHEMBL9067631 0.80 SMN1; SMN2 (0.43) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL16667594 0.79 SMN1; SMN2 (0.42) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL1856364 0.78 LMNA (0.51) SMN1; SMN2ADRA1ALMNAESR1ADORA3
SCHEMBL15312730 0.77 ADRA1A (0.58) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL139079 0.75 SMN1; SMN2 (0.49) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL6437449 0.75 SMN1; SMN2 (0.55) SMN1; SMN2NR5A2NR5A1MAPTADRA1A
SCHEMBL27575770 0.74 ADRA2A (0.47) SMN1; SMN2MAPTADRA1ALMNAADRA2A
SCHEMBL2117742 0.73 LMNA (0.54) SMN1; SMN2NR5A2NR5A1MAPTADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11931454-B2 Wet-packed soft hydrogel ocular inserts ALCON INC. (CH) 2024-03-19 US claimed
EP-4017478-A1 WET-PACKED SOFT HYDROGEL OCULAR INSERTS Alcon Inc. (CH) 2022-06-29 EP claimed
WO-2021053586-A1 WET-PACKED SOFT HYDROGEL OCULAR INSERTS ALCON INC. (CH) 2021-03-25 WO claimed
US-20210077385-A1 WET-PACKED SOFT HYDROGEL OCULAR INSERTS ALCON INC. (CH) 2021-03-18 US claimed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US claimed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP claimed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US claimed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP claimed
EP-4356169-A1 MULTIFOCAL DIFFRACTIVE SILICONE HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2024-04-24 EP disclosed
EP-4314118-A1 POLYSILOXANE VINYLIC CROSSLINKERS WITH HIGH REFRACTIVE INDEX Alcon Inc. (CH) 2024-02-07 EP disclosed
US-20240026049-A1 DUAL-PHASE ZWITTERIONIC MONOMERS Envision Biomedical LLC (US) 2024-01-25 US disclosed
WO-2023228054-A1 METHOD FOR MAKING HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-30 WO disclosed
WO-2023121292-A1 POLYMER COMPOUND AND APPLICATION THEREOF 주식회사 삼양사 2023-06-29 WO disclosed
US-20230004023-A1 DIFFRACTIVE CONTACT LENSES ALCON INC. (CH) 2023-01-05 US disclosed
US-8318824-B2 Hydrophilic polyolefin sintered body ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-11-27 US disclosed
US-20120095121-A1 HYDROPHILIC POLYOLEFIN SINTERED BODY ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-04-19 US disclosed
EP-2174975-A1 HYDROPHILIC POLYOLEFIN SINTERED BODY Asahi Kasei Chemicals Corporation (JP) 2010-04-14 EP disclosed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP disclosed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US disclosed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210077385-A1 WET-PACKED SOFT HYDROGEL OCULAR INSERTS BRI3BP, BRWD1, HRH2 SMN1; SMN2 4666/4885NR5A2 4566/4885NR5A1 4338/4885
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME C1QBP, PCTP, CD59 SMN1; SMN2 4469/4885NR5A2 4516/4885NR5A1 4526/4885
US-20240026049-A1 DUAL-PHASE ZWITTERIONIC MONOMERS RAD1, RAD51, VCL SMN1; SMN2 3505/4885NR5A2 4424/4885NR5A1 4340/4885
US-11931454-B2 Wet-packed soft hydrogel ocular inserts BRI3BP, BRWD1, HRH2 SMN1; SMN2 4666/4885NR5A2 4566/4885NR5A1 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.